Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H36N8O11 |
Molecular Weight | 588.5682 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=KQDIGHIVUUADBZ-PEDHHIEDSA-N
InChI=1S/C22H36N8O11/c23-10(7-15(32)33)17(36)29-13(9-31)18(37)28-12(8-16(34)35)20(39)30-6-2-4-14(30)19(38)27-11(21(40)41)3-1-5-26-22(24)25/h10-14,31H,1-9,23H2,(H,27,38)(H,28,37)(H,29,36)(H,32,33)(H,34,35)(H,40,41)(H4,24,25,26)/t10-,11-,12-,13-,14-/m0/s1
Pentigetide is a polar peptide derived from Immunoglobulin E (IgE) Fc region, with two acidic side chains, a basic side chain and free termini. It was developed to inhibit IgE-mediated allergic responses. A randomized, double-blind, placebo-controlled trial was conducted to evaluate the safety and efficacy of subcutaneously administered pentigetide in the treatment of allergic rhinitis. Mean symptom scores indicated that the frequency and severity of sneezing, rhinorrhea, and nasal itching decreased after 1 week of pentigetide treatment and remained decreased until study completion, whereas congestion was unchanged or slightly increased. In contrast, the frequency and severity of sneezing, rhinorrhea, and nasal itching increased after placebo treatment, with congestion essentially unchanged. No clinical or statistical differences in safety parameters between pentigetide and placebo treatments were observed. This double-blind, active-controlled trial demonstrates that pentigetide, 0.5%, ophthalmic solution is safe and effective in the treatment of allergic conjunctivitis. Pentigetide nasal solution was safe and effective for the treatment of seasonal allergic rhinitis.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Double-blind trial of pentigetide ophthalmic solution, 0.5%, compared with cromolyn sodium, 4%, ophthalmic solution for allergic conjunctivitis. | 1991 May |
|
Pentigetide nasal solution: a multicenter study evaluating efficacy and safety in patients with seasonal allergic rhinitis. | 1991 Oct |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30977675
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
100000082534
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
SUB09695MIG
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
6314
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
1362920
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
YG3J18T1UX
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
C170310
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
YG3J18T1UX
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
W-151
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
162960
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL2304033
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | |||
|
m8511
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
62087-72-3
Created by
admin on Sat Dec 16 17:43:03 GMT 2023 , Edited by admin on Sat Dec 16 17:43:03 GMT 2023
|
PRIMARY |
ACTIVE MOIETY